This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up
Mechanism of Action  Safety & Tolerability

Menu

Close

Dosing Dosing Dosing Information Dose Adjustments Drug Interactions Efficacy & Trial Design Efficacy Efficacy Trial Design Safety & Tolerability Prescribing Information
Support & ResourcesSupport &
​​​​​​​Resources
Materials Videos Frequently Asked Questions
PAXLOVID is indicated for patients* at high risk for progression to severe COVID-191Any of the following risk factors can put a patient at risk for progressing to severe COVID-19:1
  • Diabetes
  • Overweight (BMI >25)
  • Chronic lung disease (including asthma)
  • Chronic kidney disease**
  • Current smoker
  • Immunosuppressive disease or treatment
  • Cardiovascular disease
  • Hypertension
  • Sickle cell disease
  • Neurodevelopmental disorders
  • Active cancer
  • Medically related technological dependence
  • 60 years of age and older, regardless of comorbidities 
Recommendations in national guidelines may differ from the approved indications.
*Patients is defined as adults who do not require supplemental oxygen and who are at increased risk of progressing to severe disease.1
**In patients with moderate renal impairment (eGFR ≥ 30 to < 60 mL/min), the dose of Paxlovid should be reduced to nirmatrelvir/ritonavir 150 mg/100 mg every 12 hours for 5 days to avoid over-exposure. In patients with severe renal impairment [eGFR < 30 mL/min, including patients with End Stage Renal Disease (ESRD) under haemodialysis], the dose of Paxlovid should be reduced to nirmatrelvir/ritonavir 300 mg (two 150 mg tablets)/100 mg once on Day 1, followed by nirmatrelvir/ritonavir 150 mg/100 mg once daily on Days 2 to 5 to avoid over-exposure. The treatment should be administered at approximately the same time each day for 5 days. On days patients with severe renal impairment undergo haemodialysis, the dose should be administered after haemodialysis.1
Efficacy

The efficacy of PAXLOVID was evaluated in 2113 adult COVID-19 patients at high risk for progression to severe disease in the EPIC-HR trial.1,3

See the dataLoading
Drug Interaction Finder

Easily search for drug interactions by active substance name or keywords.

SearchLoading
Safety & Tolerability

During the EPIC-HR trial, comparable rates of adverse events were observed between the PAXLOVID and placebo groups.3

Find out moreLoading
How PAXLOVID Works1,4

PAXLOVID contains nirmatrelvir, a protease inhibitor specifically designed by Pfizer to target the main protease (Mpro), also known as 3-chymotrypsin-like cysteine (3CL) protease enzyme, and to inhibit SARS-CoV-2 replication by preventing proteolysis from occurring. 

Find out more Loading
Frequently Asked Questions​​​​​​​

Find answers to frequently asked questions on topics that include early treatment, dosing, and potential drug interactions.  

Frequently Asked Questions Loading

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

References:
  1. PAXLOVID Summary of Product Characteristics. https:///www.medicines.ie/medicines/paxlovid-150-mg-100-mg-film-coated-tablets-35210/spc (Accessed July 2025).
  2. Hammond J, Leister-Tebbe H, Gardner A, et al. Alleviation of COVID-19 symptoms and reduction in healthcare utilization among high-risk patients treated with nirmatrelvir/ritonavir (NMV/R): a phase 3 randomized trial. Clin Infect Dis. Published online November 11, 2024. doi.org/10.1093/cid/ciae551.
  3. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med. 2022;386(15):1397-1408.

Legal Category: S1A
Further information is available upon request

PP-C1D-IRL-0080. July 2025

Adverse events should be reported.

If you wish to make a medical information inquiry or report an adverse event please contact Pfizer on 1800 633 363 
or email Pfizer at [email protected] or visit www.PfizerMedicalInformation.ie

Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland Unlimited Company, The Watermarque Building, Ringsend Road, Dublin 4, Dublin, Ireland, D04 K7N3.  Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.  

 

Copyright © 2024 Pfizer Limited. All rights reserved.
 

PP-UNP-IRL-0891. February 2025
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland Unlimited Company.

*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0901. July 2025

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.


PP-UNP-IRL-0891. February 2025